Edition:
United States

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

6.20CAD
--
Change (% chg)

-- (--)
Prev Close
$6.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
193,403
52-wk High
$6.29
52-wk Low
$1.94

TH.TO

Chart for TH.TO

About

Theratechnologies Inc. is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess... (more)

Overall

Beta: 1.98
Market Cap(Mil.): $453.81
Shares Outstanding(Mil.): 73.20
Dividend: --
Yield (%): --

Financials

  TH.TO Industry Sector
P/E (TTM): -- 29.08 29.95
EPS (TTM): -0.02 -- --
ROI: -3.91 13.66 13.21
ROE: -5.60 14.61 14.38

BRIEF-Theratechnologies Q1 loss per share C$0.03

* Theratechnologies announces financial results for first quarter of 2017

Apr 06 2017

BRIEF-Theratechnologies Q1 loss per share C$0.03

* Theratechnologies announces financial results for first quarter of 2017

Apr 06 2017

BRIEF-Theratechnologies buys commercial rights to Ibalizumab in European Union and 4 additional territories

* Theratechnologies inc - agreement also includes upfront payment of US$3m payable through issuance of 906,077 common shares of Theratechnologies

Mar 06 2017

BRIEF-Theratechnologies announces new data from the pivotal phase III trial of Ibalizumab

* Theratechnologies announces new data from the pivotal phase III trial of HIV monoclonal antibody and long-acting investigational antiretroviral Ibalizumab

Feb 14 2017

BRIEF-Theratechnologies posts Q4 earnings per share C$0.00

* Theratechnologies announces financial results for fiscal year 2016

Feb 08 2017

BRIEF-Theratechnologies-Abstract submitted by Taimed for 24-week study of Ibalizumab phase III

* Theratechnologies-Abstract submitted by its partner, Taimed Biologics, for 24-week study of Ibalizumab phase III study has been selected for late breaker presentation Source text for Eikon: Further company coverage:

Jan 17 2017

BRIEF-Theratechnologies announces filing of final short form prospectus

* Theratechnologies announces the filing of a final short form prospectus Source text for Eikon: Further company coverage:

Nov 25 2016

BRIEF-Theratechnologies announces $16.5 mln bought deal financing

* Theratechnologies announces $16.5 million bought deal financing

Nov 14 2016

More From Around the Web

Earnings vs. Estimates